Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialScott Antonia, Emiliano Calvo|The Lancet Oncology|2016Cited by 1.3k
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive CancerAlison M. Schram, Alexander Drilon, Kōichi Goto et al.|New England Journal of Medicine|2025Cited by 104
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid TumorsMichael L. Maitland, Emiliano Calvo, Erica Stringer-Reasor et al.|Clinical Cancer Research|2021Cited by 81